28 injections! Start volume purchase (with list)

Recently, Shandong Province has been brewing for a long time 40 drugs concentrated with volume procurement officially opened.
40 varieties involved the best-selling anti-blood pressure drugs, proton pump inhibitors, contrast agents, anesthetics, anti-tumor drugs, anti-thrombosis drugs, and so on, of which 28 varieties are injections.
September 14, the Executive Meeting of the Shandong Provincial Government considered and adopted the Implementation Plan for the Centralized Belt Purchase of Pharmaceuticals and High-Value Medical Supplies in Shandong Province.
Shandong Province will be in accordance with the "belt procurement, recruitment and collection of one, quality priority, to ensure the amount of use, to ensure the return" requirements, the implementation of drugs and high-value medical supplies centralized belt procurement.
Shandong Province, the first batch of centralized drug procurement has 40 varieties, covering cardiovascular, digestive, respiratory, tumor and other clinical disciplines, is currently the national provincial procurement of the largest number of one-time centralized belt procurement of drugs in the province. according to
meters of intranet data, 40 varieties (105 product rules) in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of more than 1 billion yuan in 2019.
from the pharmaceutical dosage form, 12 of the 40 varieties are oral preparations (oral normal release dosage form, slow release control release dosage form), 28 varieties are injections.
From the field of drug treatment, the digestive system and metabolic drugs involved in 15 varieties, 6 varieties of neurological drugs, 4 varieties of blood and hema production system drugs, anti-tumor and immunomodulants, cardiovascular drugs, systemic hormone preparations (without sex hormones), hybrids have 3 varieties.
12 oral preparations, 9 varieties will have terminal sales of more than 1 billion yuan in China's public medical institutions in 2019.
, the sales of the oral normal release dosage form (2.5mg, 5mg) of left ammonia chloride (2.5mg, 5mg) exceeded 5 billion yuan, and the sales of the oral normal release agent type (10mg, 20mg) of reberazole exceeded 4.9 billion yuan.
23 of the 28 injections in China will have terminal sales of more than 1 billion yuan in public medical institutions in China in 2019.
, omeprazole injections (20mg, 40mg, 60mg) exceeded 6.6 billion yuan, and vitolazole injections (40mg, 60mg, 80mg) had sales of more than 6.1 billion yuan.
sales of 40 striped purchase varieties in Shandong Province: Mi Net Database, Shandong Province Public Resources Trading Center.